

NIBAN3 RABBIT PAB

Cat.#: S221610

Product Name: Anti-NIBAN3 Rabbit Polyclonal Antibody

Synonyms: BCNPI; FAM129C

UNIPROT ID: Q86XR2 (Gene Accession - NP_775815)

Background: FAM129C, also known as BCNPI, BCNPI is a 697 amino acid protein that belongs to the Niban family. Specifically expressed in B-lymphocytes, BCNPI exists as five alternatively spliced isoforms. BCNPI is highly expressed in B-cell malignancies, lymph node and spleen, with little to no expression in other tissues, including other hemopoietic tissues. The gene encoding the BCNPI protein maps to human chromosome 19p13.11. Consisting of around 63 million bases with over 1,400 genes, chromosome 19 makes up over 2% of human genomic DNA. Chromosome 19 includes a diversity of interesting genes and is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin superfamily members including the killer cell and leukocyte Ig-like receptors, a number of ICAMs, the CEACAM and PSG family, and Fc γ receptors. Key genes for eye color and hair color also map to chromosome 19.

Immunogen: Synthetic peptide of human NIBAN3

Applications: ELISA, IHC

Recommended Dilutions: IHC: 20-100; ELISA: 500-1000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Cell Biology

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221610 (NIBAN3 Antibody) at a dilution of 1/30 (Cytoplasm and Cell membrane).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221610 (Anti-NIBAN3 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
